Akeso, the Hong Kong-listed biotechnology company trading under ticker 9926, said it has secured Investigational New Drug (IND) clearance from China’s National Medical Products Administration for AK150, a trispecific antibody candidate intended for testing in patients with advanced solid tumors.
The company reported that news of the regulatory clearance drove its shares up about 6% to HK$117 as of 05:29 GMT on Monday.
AK150 is described by the firm as a single molecule that simultaneously targets ILT2, ILT4, and CSF1R. According to Akeso, that combination makes AK150 the only trispecific antibody currently under development that addresses those three targets together.
The candidate was developed with Akeso’s proprietary Tetrabody multispecific antibody platform, supplemented by an AI-driven drug discovery system, the company said. AK150 marks Akeso’s first trispecific antibody to reach clinical-stage development and expands its pipeline of multispecific antibody therapies focused on hard-to-treat cancers including lung, liver, and pancreatic tumors.
Operational and market context
The IND clearance initiates the transition from preclinical work to human testing for AK150, placing the asset into the clinical development phase. For investors and industry observers, the announcement underscores Akeso’s emphasis on multispecific antibodies and its use of proprietary technology and computational tools during discovery.
Information limitations
- The company statement confirms regulatory clearance to begin clinical trials but does not include detailed timelines for trial initiation, enrollment, or subsequent development milestones.
- No clinical data, projected commercialization timeline, or guidance on potential market impact for AK150 were provided in the announcement.
Implications for sectors
This development primarily affects the biotechnology and broader healthcare sectors, and it also has near-term relevance for capital markets where Akeso's shares are traded. The share movement following the clearance signals investor sensitivity to regulatory progress in the clinical development lifecycle.
The article does not include additional commentary from company executives, trial investigators, or regulatory authorities beyond the clearance announcement and the company's descriptions of the asset and its discovery platforms.